… of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer -
JC Yang, L Haworth, RM Sherry, P Hwu, DJ … - The New England Journal of Medicine - nejm.org
... Next Next. A Randomized Trial of Bevacizumab, an Anti?Vascular Endothelial
Growth Factor Antibody, for Metastatic Renal Cancer. ...
-
Obesity, Hypertension, and the Risk of Kidney Cancer in Men -
WH Chow, G Gridley, JF Fraumeni, B Jarvholm - New England Journal of Medicine, 2000 - content.nejm.org
Obesity, Hypertension, and the Risk of Kidney Cancer in Men. Wong-Ho Chow, Ph.D.,
Gloria Gridley, MS, Joseph F. Fraumeni, MD, and Bengt J?rvholm, MD, Ph.D. ...
[CITATION] Rising Incidence of Renal Cell Cancer in the United States -
WH Chow, SS Devesa, JL Warren, JF Fraumeni Jr - JAMA: The Journal of the American Medical Association, 1999 - JAMA
... Setting and Participants Patients diagnosed as having kidney cancer from 1975 through
1995 in the 9 geographic areas covered by tumor registries in the SEER ...
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer -
JC Yang, RM Sherry, SM Steinberg, SL Topalian, DJ … - Journal of Clinical Oncology, 2003 - jcojournal.org
... H. Dong, and ED Kwon Implications of B7-H1 Expression in Clear Cell Carcinoma of
the Kidney for Prognostication and Therapy Clin. Cancer Res., January 15, 2007 ...
Original Articles: Kidney Cancer: Renal Cell Carcinoma: Tumor Size, Stage and Survival -
PD Guinan, NJ Vogelzang, AM Fremgen, JS Chmiel, JL … - The Journal of Urology, 1995 - Elsevier
... Original Articles: Kidney Cancer: Renal Cell Carcinoma: Tumor Size, Stage and Survival. ...
16. 3 Kidney Cancer, Results in Treating Cancer, Report No. ...
CXCR4/CXCL12 expression and signalling in kidney cancer. -
AJ Schrader, O Lechner, M Templin, KE Dittmar, S … - Br J Cancer, 2002 - ncbi.nlm.nih.gov
... selection through MyNCBI. 1: Br J Cancer. 2002 Apr 22;86(8):1250-6.Links.
CXCR4/CXCL12 expression and signalling in kidney cancer. ...
Kidney cancer. -
NJ Vogelzang, WM Stadler - Lancet, 1998 - ncbi.nlm.nih.gov
... Kidney cancer. Vogelzang NJ, Stadler WM. ... njvogelz@mcis.bsd.uchicago.edu In the USA,
the incidence of kidney cancer has increased 43% since 1973. ...
… tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo …
AR Zlotta, T Wildschutz, G Raviv, MO Peny, D van … - J Endourol, 1997 - ncbi.nlm.nih.gov
Radiofrequency interstitial tumor ablation (RITA) is a possible new modality
for treatment of renal cancer: ex vivo and in vivo experience. ...
Immunological and Clinical Responses in Metastatic Renal Cancer Patients Vaccinated with Tumor RNA- … -
Z Su, J Dannull, A Heiser, D Yancey, S Pruitt, J … - Cancer Research, 2003 - AACR
... Experimental Therapeutics. Immunological and Clinical Responses in Metastatic Renal
Cancer Patients Vaccinated with Tumor RNA-transfected Dendritic Cells 1. ...
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4 -
PT Golumbek, AJ Lazenby, HI Levitsky, LM Jaffee, H … - Science, 1991 - sciencemag.org
... 18 March 1991; accepted 21 May 1991 Treatment of Established Renal Cancer
by Tumor Cells Engineered to Secrete Interleukin-4 PAUL ...
Source: Google Scholar |